Cancer Research and Biotechnology AG is a Swiss biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics.

 

Cancer affects not only humans but a broad range of terrestrial and aquatic species. This phenomenon of uncontrolled cell division has the ability to target multiple organs and organ systems thereby challenging the survival of a life form. Currently, many cures and claims for cures exist to battle cancer. They range from targeting the cancer directly to educating the immune system to recognize and terminate the cancerous cells. In these therapies the root cause of cancer is side-lined where the importance is given directly to the cancer itself. Such an approach is beneficial on the short run but does not necessarily guarantee risk reduction of the survivor in the long run. Thus, tackling one of the root causes of cancer is the main aim Cancer Research and Biotechnology AG.

 

Cancer Research and Biotechnology AG is devoted to investigating the fundamental mechanisms causing cancer and related degenerative disorders, such as Alzheimer’s and Parkinson’s diseases, and to developing life-saving  solutions. The solutions are directed at prevention, screening, early diagnosis and treatment of these diseases. 

Cancer Research and Biotechnology AG is a Swiss biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics.

 

Cancer affects not only humans but a broad range of terrestrial and aquatic species. This phenomenon of uncontrolled cell division has the ability to target multiple organs and organ systems thereby challenging the survival of a life form. Currently, many cures and claims for cures exist to battle cancer. They range from targeting the cancer directly to educating the immune system to recognize and terminate the cancerous cells. In many of these therapies the root cause of cancer is side-lined where the importance is given directly to the cancer itself. Such an approach is beneficial on the short run but does not necessarily guarantee risk reduction of the survivor in the long run. Thus, tackling one of the root causes of cancer is the main aim Cancer Research and Biotechnology AG has realised and taken up as challenge. 

Cancer Research and Biotechnology AG is devoted to investigating the fundamental mechanisms causing cancer and related degenerative disorders, such as Alzheimer’s and Parkinson’s diseases, and to developing novel, life-saving management solutions to these diseases. The solutions are directed at prevention, screening, early diagnosis and treatment of these diseases. 

Today, “Cancer” is defined as a “Tumor”.

 

CRAB redefines the problem of carcinogenesis.

 

Cancer is currently diagnosed in late stages (tumors with more than 10 million cells) and it is seen as a genetic disease by origin. Current therapies aim at eliminating tumors, not the underlying disease that causes the damage in the DNA.

 

CRAB redefines cancer as an early metabolic disease (in individual cells) caused by aberrant intracellular mechanisms.

 

This creates an opportunity to develop first-in-class medicinal products that have the potential to prevent and cure cancers. Cells renew themselves, on average, every two weeks. What if the next generation  of cells had no DNA damage?

Today, “Cancer” is defined as a “Tumor”.

 

CRAB redefines the problem of carcinogenesis.

 

Cancer is currently diagnosed in late stages (tumors with more than 10 million cells) and it is seen as a genetic disease by origin. Current therapies aim at eliminating tumors, not the underlying disease that causes the damage in the DNA.

 

CRAB redefines cancer as an early metabolic disease (in individual cells) caused by aberrant intracellular mechanisms.

 

This creates an opportunity to develop first-in-class medicinal products that have the potential to prevent and cure cancers. Cells renew themselves, on average, every two weeks. What if the next generation  of cells had no DNA damage?